TB-500 Side Effects: What the Research Reports | MD/TB-500
TB-500 Side Effects: What the Research Reports
TB-500 side effects documented in the peer-reviewed literature are primarily derived from preclinical animal studies and from Phase 1-2 human studies of the full-length thymosin beta-4 parent protein. No human safety trial of the TB-500 heptapeptide (Ac-LKKTETQ) specifically has been published.
The Phase 1 IV study of full-length thymosin beta-4 in healthy volunteers across four ascending dose cohorts (42-1260 mg) reported no dose-limiting toxicity [9]. The first-in-human recombinant Tβ4 Phase 1 study in 84 Chinese volunteers reported adverse events were mild to moderate with no serious adverse events [12]. Phase 2 topical thymosin beta-4 in wound patients was judged safe and well-tolerated at all doses tested [6].
Animal studies note transient fatigue, injection-site irritation, and mild nausea as observations. Systematic dose-toxicity data specifically for the TB-500 heptapeptide in rodents are sparse in the published literature.
Three categories of concern require specific attention: tumor-promotion, anti-doping status, and theoretical contraindications.
Most Common Side Effects Reported in Studies
The adverse event profile from the full-length thymosin beta-4 Phase 1 studies [9] [12] documented mild-to-moderate events with no dose-limiting toxicities. Specific adverse events from these studies were not enumerated in the publicly available abstracts.
Anecdotal reports from animal research and equine settings describe: local injection-site reactions (erythema, swelling), transient fatigue, and mild gastrointestinal symptoms. These observations are consistent with non-specific peptide injection responses and have not been systematically characterized in controlled toxicity studies for TB-500 specifically.
The Phase 2 topical thymosin beta-4 wound healing studies in human patients with venous ulcers and pressure ulcers reported safety and tolerability at all dose cohorts tested [6] [7]. Topical application to dermal wounds is a meaningfully different route and exposure profile compared to systemic injection.
TB-500 and Tumor Growth: What Research Says
Can TB-500 cause cancer or tumor growth? This question is among the most important in the TB-500 safety literature, and the answer from the data is: a specific concern exists from one mechanistic study, but it has not been replicated in standard preclinical toxicity protocols.
In a mouse melanoma model, thymosin beta-4 expressed by adenoviral vector produced tumor sizes of 21.7 mm versus 13.3 mm in controls, and lung metastasis nodule counts of 46.7 versus 10.9 [17]. The proposed mechanism is VEGF-driven angiogenesis and enhanced cell migration under conditions of existing malignancy — the same pathways that promote tissue repair in normal wound contexts.
This finding is specific to a context of active malignancy combined with deliberate viral overexpression of the protein. No direct tumor-promotion has been observed in standard rodent toxicity protocols using TB-500 at research doses. The systemic angiogenic effects via the VEGF pathway raise a theoretical concern for off-target vascular growth, but no adverse vascular events have been documented in standard preclinical toxicity studies.
The question remains unresolved in long-duration studies and in subjects with pre-existing malignancies. Active malignancy or history of malignancy is the primary theoretical contraindication flagged in review literature.
TB-500 Safety Profile in Preclinical Research
Is TB-500 safe? Is it safe to take a TB-500 peptide? Short-term preclinical safety data from animal models and from full-length thymosin beta-4 Phase 1 human studies are generally favorable. No validated human safety data exist for the TB-500 heptapeptide fragment specifically.
The evidence summary:
- Phase 1 IV thymosin beta-4 in healthy volunteers: no dose-limiting toxicity across four dose cohorts [9].
- First-in-human recombinant Tβ4 Phase 1: no serious adverse events in 84 volunteers [12].
- Phase 2 topical wound healing: safe and well-tolerated [6] [7].
- Standard rodent toxicity: no adverse vascular events or systemic toxicity documented at research doses.
Hormonal effects: TB-500 acts via actin-cytoskeletal and integrin-linked kinase signaling pathways, not directly on the hypothalamic-pituitary-gonadal or adrenal axes. Endocrine disruption has not been observed in standard preclinical toxicity studies.
None of the above constitutes a human safety profile for the heptapeptide fragment at any dose or route.
TB-500 and Anti-Doping Status
What are the implications of anti-doping regulations for athletes considering TB-500? TB-500 is explicitly prohibited by the World Anti-Doping Agency (WADA) under the annual Prohibited List as a Non-Specified Substance banned both in and out of competition. It falls under two categories: S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances).
The Banned Substances Control Group (BSCG) has documented sport bans from TB-500 positives. The Canadian Centre for Ethics in Sport issued a four-year ineligibility period for non-analytical positive findings involving TB-500.
WADA-accredited labs can detect TB-500 (Ac-LKKTETQ) via LC-MS/MS in equine and human urine. The first published detection method achieved limits of 0.02 ng/mL in equine plasma and 0.01 ng/mL in equine urine [8]. Competitive athletes testing positive for Ac-LKKTETQ face sanctions under applicable sport codes.
For anti-doping status and legal notes, see the FAQ page.
TB-500 Contraindications in the Research Literature
Are there specific contraindications to the use of TB-500? The research literature and review papers flag several theoretical contraindications based on the compound's known mechanism:
Active malignancy. The VEGFR2-driven angiogenic mechanism documented in the melanoma mouse model [17] raises a theoretical contraindication in subjects with active or recently treated malignancy. No direct evidence of tumor-promotion at standard research doses exists, but the mechanistic concern is substantive.
Pregnancy. Standard caution in the absence of safety data. No thymosin beta-4 or TB-500 pregnancy safety studies have been published.
Autoimmune conditions. TB-500's immune-modulating properties (NF-kB inhibition, cytokine suppression) carry theoretical interactions with autoimmune disease states.
Pre-existing thyroid disorders. Flagged as a caution in some review literature; no direct thyroid interaction has been documented in preclinical studies.
These are theoretical contraindications derived from mechanism-based reasoning and review literature, not from controlled human safety data. The absence of human trial data means no evidence-based contraindication list can be established.
TB-500 and Hormonal Effects
Does TB-500 have any hormonal side effects? TB-500 acts via actin-cytoskeletal and integrin-linked kinase (ILK) signaling, not directly on hormonal axes. The mechanism documented in preclinical studies — G-actin sequestration, ILK/PINCH/Akt activation, NF-kB inhibition, VEGF modulation — does not involve the hypothalamic-pituitary-gonadal axis, adrenal axis, or thyroid axis directly.
Endocrine disruption has not been observed in standard preclinical toxicity protocols for thymosin beta-4 at research doses. The full-length thymosin beta-4 Phase 1 human safety studies [9] [12] did not report endocrine adverse events.
TB-500 is not a growth hormone secretagogue (unlike CJC-1295 or ipamorelin) and does not act on GHS receptors. It does not affect LH, FSH, testosterone, or cortisol via any documented direct mechanism.
Allergic and Immune Reactions to TB-500
Can TB-500 peptide cause allergic reactions? Hypersensitivity reactions are theoretically possible with any exogenous peptide. As a heptapeptide derived from an endogenous human protein (thymosin beta-4), the immunogenic potential is relatively low compared to foreign proteins — the sequence is human-derived and the immune system is tolerant to endogenous thymosin beta-4.
Anecdotal reports describe local injection-site reactions (erythema, transient swelling), consistent with non-specific peptide injection responses. Systematic allergy and hypersensitivity data from controlled studies are absent for TB-500 specifically.
The human Phase 1 studies of full-length thymosin beta-4 [9] [12] and the Phase 2 wound healing studies [6] [7] did not document systemic hypersensitivity or anaphylaxis events. These studies used the full-length protein, not the heptapeptide fragment, and were conducted under controlled trial conditions.